AEON (AEON Biopharma Inc.) Net earnings per share (EPS TTM)

AEON Bio (AEON) - corporate logo

Analyzing the rolling annual EPS growth chart on GURU.Markets, we see that AEON Biopharma (AEON) has stabilized this parameter at 35.30. Volatility is driven by concerns over failed drug trials and a lack of profitability. However, AEON Biopharma (AEON) is attracting top chemists through lucrative benefits packages. Prospects are bolstered by the protection of migraine treatment rights and stringent regulatory requirements for new market entrants.

AEON Bio - AEON Earnings per share for the last twelve months (period 11/23/2025 - 11/16/2026)

AEON (AEON Bio): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental company valuation:AEON AEON Biopharma
Flagship merchandise of AEON Biopharma Inc.

The indicator is calculated as the percentage change in net income per share over the last twelve months relative to the same period last year. This metric measures the dynamics of capital generation efficiency, accounting for currency fluctuations. For AEON Biopharma (AEON), this growth reflects the monetization of highly specialized neurotoxins within medical niches. The positive trend confirms the market expansion of the drugs. By analyzing the comparable year-over-year growth of EPS TTM, an investor assesses the sustainability of the issuer's dollar margin.

Direct competitors

Net earnings per one share for the last twelve months Jazz Pharma|CYTK (Cytokinetics Inc.) - Net earnings per share for the last 12 months|PTC Bio (PTCT) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Scholar Rock|CNTA: Earnings per share for the trailing year|Earnings per share for the last twelve months Dyne Therapeutics (DYN)|EWTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Rapport Pharma RAPP|Alumis Pharma - Earnings per share for the last twelve months|ZVRA - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Contineum Therapeutics, Inc.|LRMR: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Capricor Therapeutics CAPR|Net earnings per share for the last 12 months TRDA|Net earnings per one share for the last twelve months Channel PTHS|Earnings per share for the last twelve months MediciNova Inc. (MNOV)|SER - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Net earnings per one share for the last twelve months|Apimeds Pharmaceuticals, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters NLS Pharmaceutics Ltd. NLSP|Bionomics Limited (BNOX) - Earnings per share for the last twelve months|fsdpharma.com - Earnings per share for the trailing year|RETA (reatapharma.com) - Net earnings per share (EPS TTM)